Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
Abstract
Neutropenia is one of the most important dose-limiting toxicities and often the reason for dose reduction. In this study we aimed to assess whether chemotherapy-induced neutropenia could be a marker of efficacy and associate with increased survival. Data from a retrospective survey for early breast cancer patients in our hospital were reviewed. Three hundred and thirty-five patients who had been treated with six cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF) were studied. The association between chemotherapy-induced neutropenia and overall survival (OS) was assessed. According to a multivariate Cox model with time-varying covariates, hazard ratios of death were 0.434 (95% confidence interval (CI), 0.298-0.634; P < 0.001) for patients with mild neutropenia, and 0.640 (95% CI, 0.42-0.975; P = 0.038) for those with severe neutropenia. Neutropenia occurring in early breast cancer patients is an independent predictor of increased survival. These findings suggest that neutropenia in patients who receive chemotherapy is strongly associated with a better prognosis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Chemotherapy-induced neutropenia has predicted improved survival rates among cancer patients.
“chemotherapy induced neutropenia has also predicted improved survival rates among cancer patients [12–17]”
Long-term survival of breast cancer patients receiving chemotherapy is higher for patients with mild chemotherapy-induced neutropenia.
“Notably, long-term survival of breast cancer patients receiving chemotherapy is higher for patients with mild chemotherapy-induced neutropenia (32).”
From Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps (2016) · cites this paper as [32]
Cites
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146 · see citing works
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,040 · see citing works
Henderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C., Goldstein, L. J., Martino, S., Ingle, J. N., Cooper, M. R., Hayes, D. F., Tkaczuk, K. H. R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.063 · Cited by 1,291 · see citing works
Adjuvant Docetaxel for Node-Positive Breast Cancer
Martín, M., Pieńkowski, T., Mackey, J. R., Pawlicki, M., Guastalla, J., Weaver, C. H., Tomiak, E. M., Al‐Tweigeri, T., Chap, L. I., Juhos, É., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043681 · Cited by 965 · see citing works
Anemia as an independent prognostic factor for survival in patients with cancer
Caro, J. J., Salas, M., Ward, A., & Goss, G. D. (2001) · Cancer · doi:10.1002/1097-0142(20010615)91:12 · Cited by 947 · see citing works
Chemotherapy‐induced neutropenia
Crawford, J., Dale, D. C., & Lyman, G. H. (2004) · Cancer · doi:10.1002/cncr.11882 · Cited by 887 · see citing works
Triple-negative breast cancer—current status and future directions
Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U. A., & Harbeck, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp492 · Cited by 682 · see citing works
Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
Wood, W. C., Budman, D. R., Korzun, A. H., Cooper, M. R., Younger, J., Hart, R. D., Moore, A. L., Ellerton, J. A., Norton, L., Ferree, C. R., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301801 · Cited by 583 · see citing works
Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
(1994) · New England Journal of Medicine · doi:10.1056/nejm199407143310226 · Cited by 556 · see citing works
Lyman, G. H., Dale, D. C., & Crawford, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.002 · Cited by 465 · see citing works
Gurney, H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.9.2590 · Cited by 363 · see citing works
Bergh, J. C. S., Wiklund, T. A., Erikstein, B., Lidbrink, E. K., Lindman, H., Malmström, P., Kellokumpu‐Lehtinen, P., Bengtsson, N., Söderlund, G., Anker, G. B., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02841-5 · Cited by 338 · see citing works
Lyman, G. H., Dale, D. C., Friedberg, J. W., Crawford, J., & Fisher, R. I. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.213 · Cited by 315 · see citing works
Fisher, B., Anderson, S., Wickerham, D. L., DeCillis, A. P., Dimitrov, N. S., Mamounas, E. P., Wolmark, N., Pugh, R., Atkins, J. N., Meyers, F. J., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1858 · Cited by 308 · see citing works
Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001
Baker, S. D., Verweij, J., Rowinsky, E. K., Donehower, R. C., Schellens, J. H. M., Grochow, L. B., & Sparreboom, A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.24.1883 · Cited by 286 · see citing works
How to calculate the dose of chemotherapy
Gurney, H. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600139 · Cited by 252 · see citing works
Maïo, M. D., Gridelli, C., Gallo, C., Shepherd, F. A., Piantedosi, F. V., Cigolari, S., Manzione, L., Illiano, A., Barbera, S., Robbiati, S. F., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70255-2 · Cited by 235 · see citing works
Martín, M., Villar, A., Sole-Calvo, A., Gonzalez, R., Massutí, B., Lizón, J., Camps, C., Carrato, A., Casado, A., Candel, M. T., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg260 · Cited by 188 · see citing works
Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?
Ratain, M. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2297 · Cited by 178 · see citing works
Influence of Sex on Toxicity and Treatment Outcome in Small-Cell Lung Cancer
Singh, S., Parulekar, W. R., Murray, N., Feld, R. D., Evans, W. K., Tu, D., & Shepherd, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.171 · Cited by 141 · see citing works
Selection of adjuvant chemotherapy for treatment of node-positive breast cancer
Trudeau, M., Charbonneau, F., Gelmon, K. A., Laing, K. E., Latreille, J., Mackey, J. R., McLeod, D., Pritchard, K. I., Provencher, L., & Verma, S. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70424-1 · Cited by 136 · see citing works
Pettengell, R., Schwenkglenks, M. M., Leonard, R. C., Bosly, A., Paridaens, R., Constenla, M., Szucs, T. D., & Jackisch, C. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-008-0430-4 · Cited by 136 · see citing works
Saarto, T., BLOMQVIST, C. P., Rissanen, P., Auvinen, A. P., & Elomaa, I. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.49 · Cited by 128 · see citing works
Body-Surface Area–Based Dosing Does Not Increase Accuracy of Predicting Cisplatin Exposure
de Jongh, F. E., Verweij, J., Loos, W. J., de Wit, R., de Jonge, M. J. A., Planting, A. S. T., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.17.3733 · Cited by 119 · see citing works
Gurney, H., Ackland, S. P., Gebski, V., & Farrell, G. C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2299 · Cited by 119 · see citing works
Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer
Cameron, D., Massie, C. E., Kerr, G. R., & Leonard, R. C. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601366 · Cited by 117 · see citing works
Poikonen‐Saksela, P., Saarto, T., Lundin, J. E., Joensuu, H., & BLOMQVIST, C. P. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690594 · Cited by 113 · see citing works
on behalf of the UK Breast Cancer Neutropenia Audit Group, Leonard, R. C., Miles, D., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601279 · Cited by 100 · see citing works
Yamanaka, T., Matsumoto, S., Teramukai, S., Ishiwata, R., Nagai, Y., & Fukushima, M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603831 · Cited by 86 · see citing works
Shitara, K., Matsuo, K., Takahari, D., Yokota, T., Inaba, Y., Yamaura, H., Sato, Y., Najima, M., Ura, T., & Muro, K. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.01.019 · Cited by 83 · see citing works
Sandström, M., Freijs, A., Larsson, R. L., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1581 · Cited by 70 · see citing works
Sandström, M., Lindman, H., Nygren, P., Johansson, M., Bergh, J. C. S., & Karlsson, M. O. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0140-2 · Cited by 68 · see citing works
The leucocyte nadir, a predictor of chemotherapy efficacy?
Kvinnsland, S. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690583 · Cited by 38 · see citing works
Getting the right dose in cancer chemotherapy – time to stop using surface area?
Newell, D. R. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600226 · Cited by 27 · see citing works
Khardori, N. M., Berkey, P., Hayat, S., Rosenbaum, B., & Bodey, G. P. (1989) · Cancer · doi:10.1002/1097-0142(19891101)64:9 · Cited by 25 · see citing works
Developing a New Framework for Dose Calculation
Gurney, H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1607 · Cited by 19 · see citing works
Premenopausal Patients with Node-Positive Resectable Breast Cancer
Fumoleau, P., Devaux, Y., Van, M. L. V., Kerbrat, P., Fargeot, P., Schraub, S., Mihura, J., Namer, M., & Mercier, M. (1993) · Drugs · doi:10.2165/00003495-199300452-00007 · Cited by 17 · see citing works
Ishitobi, M., Komoike, Y., Motomura, K., Koyama, H., & Inaji, H. (2010) · Oncology · doi:10.1159/000313702 · Cited by 13 · see citing works
Edlund, P., Ahlgren, J., Bjerre, K., et al. (2011) · Acta Oncologica · doi:10.3109/0284186x.2011.554435 · Cited by 11 · see citing works
Nakata, B., Tsuji, A., Mitachi, Y., et al. (2006) · Clinical Oncology · doi:10.1016/j.clon.2006.07.007 · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Neutrophils in cancer: Neutral no more
Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830 · see citing works
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Coffelt, S. B., Kersten, K., Doornebal, C. W., Weiden, J., Vrijland, K., Hau, C.-S., Verstegen, N. J. M., Ciampricotti, M., Hawinkels, L. J. A. C., Jonkers, J., et al. (2015) · Nature · doi:10.1038/nature14282 · Cited by 1,703 · see citing works
Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps
Park, J., Wysocki, R. W., Amoozgar, Z., Maiorino, L., Fein, M. R., Jorns, J., Schott, A. F., Kinugasa-Katayama, Y., Lee, Y., Won, N. H., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1711 · Cited by 984 · see citing works
Surendran, V., Rutledge, D., Colmon, R., & Chandrasekaran, A. (2021) · Biofabrication · doi:10.1088/1758-5090/abe1cf · Cited by 99 · see citing works
Kasi, P. M., & Grothey, A. (2018) · Drugs · doi:10.1007/s40265-018-0909-3 · Cited by 80 · see citing works
Prognostic value of chemotherapy-induced neutropenia at the first cycle in invasive breast cancer
Ma, R.-M., Chen, C.-Z., Zhang, W., You, J., Huang, D.-P., & Guo, G.-L. (2016) · Medicine · doi:10.1097/md.0000000000003240 · Cited by 23 · see citing works
He, Y., Li, T., Liu, J., Ou, Q., & Zhou, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-6609-x · Cited by 11 · see citing works
- Authors
- Han, Y., Yu, Z., Wen, S., Zhang, B., Cao, X., & Wang, X.
- Affiliations
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Corresponding author
- Wang, Xin
- Venue
- Breast Cancer Research and Treatment
- Published
- 2011-10-05
- Volume
- 131
- Issue
- 2
- Pages
- 483-490
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2054098785
- Cited by
- 69
- References
- 41
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 5 · 2022: 6 · 2021: 5 · 2020: 8 · 2019: 4 · 2018: 7 · 2017: 9 · 2016: 9 · 2015: 6 · 2014: 2 · 2013: 3 · 2012: 3
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Keywords
- chemotherapy-induced neutropenia, early breast cancer, prognostic factors, overall survival, CEF chemotherapy, cyclophosphamide, epirubicin, 5-fluorouracil, dose-limiting toxicity, time-varying covariates
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Middle Aged, Neoplasm Staging, Neutropenia, Prognosis, Time Factors, Incidence, Survival Analysis, Chemotherapy, Adjuvant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
